Cooper Pharma
Cooper Pharma is a privately held Moroccan pharmaceutical group founded in 1933 that manufactures and distributes branded generics and in-licensed products across Africa, Europe, and the Middle East, leading the Moroccan market with 9.4% share via 1,001-5,000 employees and 9 domestic distribution centers.
- Company typePrivate
- Founded1933
- HeadquartersCasablanca, Morocco
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cooper Pharma does
Cooper Pharma is a privately held Moroccan pharmaceutical group founded in 1933, headquartered in Casablanca, operating across three continents (Africa, Europe, Middle East) with 1,001-5,000 employees. Its core business spans pharmaceutical manufacturing of branded generic drugs and in-licensed products for approximately 15 multinational partner laboratories (including Pfizer, Merck, Abbott, Daiichi Sankyo, Dr. Reddy's, and Cipla), complemented by an in-house distribution network of 9 centers covering all regions of Morocco. The company holds the #1 position in the Moroccan pharmaceutical market with 9.4% share (IQVIA, 2022). Specialized manufacturing capabilities include solid, liquid, and pasty formulations at the 20,000 sqm Tit Mellil plant (45 million units/year), effervescent tablet production at MC Pharma, contraceptive hormone manufacturing at Gynebio Pharma (launched 2019, first such African site), and incremental R&D in galenic formulations at IDC Pharma. International operations span manufacturing plants in Côte d'Ivoire, Rwanda (Cooper Pharma East Africa, Q4 2021), Saudi Arabia (including Cooper Pharma Arabia and the SPIMACO JV Dammam Pharma), along with offices in the UAE, Spain (EDDA Pharma, Redox Pharma), and the Czech Republic (via Rougier acquisition). Beyond pharma manufacturing and distribution, the group operates Cooper Biosciences focused on biotechnology innovation and biosimilars in the MENA region. Quality and compliance are anchored in GMP (Morocco), AFSSAPS/ANSM (France, 2008), Saudi FDA (2011), UAE Manufacturing Site Registration (2015), and Libyan (2023) certifications, supporting a sales-led go-to-market built around the largest pharmaceutical field sales network in Morocco and abroad, run on a personalized CRM, with marketing supported by medical caravans, social media, and ESG programs covering 50+ foundations in health, education, and environment.
Cooper Pharma firmographics
Firmographics- Name
- Cooper Pharma
- Legal name
- Cooper Pharma
- Website
- https://cooperpharma.ma
- Company type
- Private
- Founded year
- 1933
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Cooper Pharma is a privately held Moroccan pharmaceutical group founded in 1933 that manufactures and distributes branded generics and in-licensed products across Africa, Europe, and the Middle East, leading the Moroccan market with 9.4% share via 1,001-5,000 employees and 9 domestic distribution centers.
- Ownership category
- akta.pro rank
Cooper Pharma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Pharmaceutical Distributors (HLAIAJAB)
- akta.pro secondary industries
- Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA), Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)
Keywords
Where Cooper Pharma is headquartered
LocationHeadquarters
- HQ city
- Casablanca
- HQ country
- Morocco
- HQ region
- Africa
Offices14 records
Markets served
Cooper Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D
Revenue model
- Pharmaceutical Manufacturing: Manufacturing of branded generic and innovative drugs compliant with international quality standards. Production of 200+ specialties in nearly 300 presentations. Includes own Cooper-branded generics and originator medicines manufactured for international laboratories.
- Distribution: Own distribution network of 9 distribution centers covering all regions of Morocco. Reduces delivery times to pharmacies, making medicines accessible to the public.
- Licensed Product Distribution: Distribution of pharmaceutical products under license from approximately 15 multinational laboratories. Represents about 100 medications under license, complementing own product portfolio.
- Export: International export activities to Africa, Europe, and Middle East regions, making exports a key lever for international competitiveness and development.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Cooper Pharma product offering
Product offeringCore offering
Cooper Pharma manufactures and distributes pharmaceutical products, operating as a producer, distributor, and exporter of branded generic and licensed originator medicines. The company produces 200+ specialties in nearly 300 presentations across major therapeutic areas, complemented by 100+ in-licensed products from approximately 15 multinational partner laboratories. Operations span 6 manufacturing facilities across Africa, Europe, and the Middle East, supported by 9 distribution centers in Morocco and international export activities to 12+ countries.
Product overview
Cooper Pharma is a Moroccan pharmaceutical company offering a dual product portfolio: (1) Cooper-branded generic pharmaceuticals covering over 200 specialities across major therapeutic areas, and (2) licensed pharmaceutical products manufactured or distributed for approximately 15 multinational partner laboratories. The company operates multiple specialized production facilities including Tit Mellil (solid, liquid, pasty products), MC Pharma (effervescent tablets), Gynebio Pharma (contraceptive hormones), IDC Pharma (R&D and incremental development), and CIPLA JV (respiratory/CNS therapies). Distribution is handled through a network of 9 regional centers across Morocco. International operations include Cooper Biosciences for biotech innovation in MENA.
Differentiator
Problem solved
Functional benefit
Products and services
- Cooper Generic Pharmaceuticals Cooper-branded generic pharmaceutical products covering major therapeutic areas with over 100 specialties and totaling 200+ specialties in nearly 300 presentations across the company's portfolio. Distributed through pharmacy networks across Morocco and exported to Africa, Europe, and the Middle East.
- Licensed Partner Pharmaceuticals Pharmaceutical products manufactured or distributed under license from approximately 15 multinational pharmaceutical laboratories including Pfizer, Merck, Abbott Laboratories, Daiichi Sankyo, Pierre Fabre, Almirall, and others. Represents roughly 100 medications covering major therapeutic areas.
Quantifiable outcome
- 9.4% pharmaceutical market share in Morocco (2022) - ranked N°1
- +2 more outcomes
Companies that use Cooper Pharma
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Cooper Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cooper Pharma partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core and minor.
- PfizercoreManufacturing and distribution partnership for pharmaceutical products in Morocco and regional markets
- Mayoly SpindlercoreLicensed manufacturing and distribution partnership for pharmaceutical products
- MerckcoreLicensed manufacturing and distribution partnership for pharmaceutical products
- THEAcoreLicensed manufacturing and distribution partnership for pharmaceutical products
- Abbott LaboratoriescoreLicensed manufacturing and distribution partnership for pharmaceutical products
- Pierre FabrecoreLicensed manufacturing and distribution partnership for pharmaceutical products
- AlmirallcoreLicensed manufacturing and distribution partnership for pharmaceutical products
- Daiichi SankyocoreLicensed manufacturing and distribution partnership for pharmaceutical products
- Dr. Reddy's LaboratoriescoreLicensed manufacturing and distribution partnership for pharmaceutical products
- CiplacoreJoint venture partnership for respiratory and CNS therapies. Cooper Pharma increased ownership from 15.8% to 24.9% to strengthen leadership position.
- Foundation Mohammed VI for Environmental ProtectionminorEnvironmental protection partnership through active participation in foundation's projects
- Zakoura Education FoundationminorEducation sector partnership for early childhood education development in Morocco
- Al Jisr AssociationminorEducation sector partnership supporting Moroccan educational system development
- Injaz Al MaghribminorEducation and entrepreneurship initiative partnership in Morocco
- SPIMACOcoreJoint venture Dammam Pharma with Saudi Arabia's leading pharmaceutical company for new manufacturing plant development
- BiocodexcoreLicensed manufacturing and distribution partnership for pharmaceutical products
- BiofarcoreLicensed manufacturing and distribution partnership for pharmaceutical products
- LALLEMANDcoreLicensed manufacturing and distribution partnership for pharmaceutical products
- Iprad PharmacoreLicensed manufacturing and distribution partnership for pharmaceutical products
Scale indicators13 records
Recent moves9 records
Expansion highlights6 records
Cooper Pharma competitors and assessment
Company assessmentDirect peers
- Cipla: Indian generic pharmaceutical major and Cooper Pharma's JV partner in Cipla Maroc. Direct comparable in respiratory and CNS therapy focus, branded generic portfolio, and emerging markets distribution model.
- Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with manufacturing plants across the MENA region. Comparable to Cooper Pharma in generic manufacturing, in-licensing of international brands, and regional distribution focus.
- Hikma Pharmaceuticals: Jordan-headquartered generic and specialty pharmaceutical manufacturer with a strong MENA and North African footprint. Directly comparable to Cooper Pharma in business model (branded generics + in-licensed products), therapeutic breadth, and regional distribution focus.
- Aspen Pharmacare: South African pharmaceutical group with manufacturing and distribution across sub-Saharan Africa, Europe, and the Middle East. Highly comparable to Cooper Pharma as a regional pharma champion expanding from an African anchor into international markets via acquisition and licensing.
- Dr. Reddy's Laboratories: Indian pharmaceutical company and one of Cooper Pharma's in-licensing partners. Comparable in generic drug manufacturing for global markets, API and finished dosage form production, and emerging markets commercialization strategy.
- SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi Arabia's leading pharmaceutical manufacturer and Cooper's JV partner in Dammam Pharma. Directly comparable in MENA-focused branded generic manufacturing, regional distribution, and partnerships with multinational originators.
Regional players
- EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest pharmaceutical manufacturers in Egypt and the MENA region, with a similar portfolio of generics and licensed products. Comparable as a regional pharma manufacturer primarily serving MENA markets, though Egypt-domiciled.
Broad incumbents
- Merck (North Africa/MENA operations): Global pharmaceutical and life sciences company with a North Africa presence and an in-licensing partnership with Cooper Pharma. Broader incumbent competing on originator products while leveraging Cooper for last-mile distribution in selected markets.
- Pfizer (North Africa operations): Global pharmaceutical leader and one of Cooper Pharma's key in-licensing partners. A broad incumbent that supplies Morocco through both direct operations and the Cooper distribution partnership, competing for shelf space and prescriber mind-share.
- Sanofi (North Africa/MENA operations): Global pharmaceutical major with a significant North Africa and MENA presence, including local manufacturing and distribution partnerships. Broader incumbent that competes with Cooper across both originator and generic segments, with much larger scale and pipeline depth.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Cooper Pharma social profiles
Digital presenceCooper Pharma compliance and trust
Trust signalCompliance6 records
Cooper Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cooper Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Cooper Pharma subsidiaries and ownership
Company hierarchySubsidiaries16 records
Cooper Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cooper Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cooper Pharma
What does Cooper Pharma do?
Cooper Pharma manufactures and distributes pharmaceutical products, operating as a producer, distributor, and exporter of branded generic and licensed originator medicines. The company produces 200+ specialties in nearly 300 presentations across major therapeutic areas, complemented by 100+ in-licensed products from approximately 15 multinational partner laboratories. Operations span 6 manufacturing facilities across Africa, Europe, and the Middle East, supported by 9 distribution centers in Morocco and international export activities to 12+ countries.
Is Cooper Pharma a public or private company?
Cooper Pharma is a private company. It is classified as family owned and is currently operating.
When was Cooper Pharma founded?
Cooper Pharma was founded in 1933. It employs 1,001 to 5,000 people.
Where is Cooper Pharma based?
Cooper Pharma is headquartered in Casablanca, Morocco, in the Africa region.
How does Cooper Pharma make money?
Four revenue lines are on record. Pharmaceutical Manufacturing is the primary driver. The others are distribution, licensed Product Distribution and export.
Who are Cooper Pharma's main competitors?
Direct peers on record are Cipla, Julphar (Gulf Pharmaceutical Industries), Hikma Pharmaceuticals, Aspen Pharmacare, Dr. Reddy's Laboratories and SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances). EIPICO (Egyptian International Pharmaceutical Industries Company) is listed as a regional player. Broad incumbents are Merck (North Africa/MENA operations), Pfizer (North Africa operations) and Sanofi (North Africa/MENA operations).
Does Cooper Pharma have an API?
No public API is recorded for Cooper Pharma.
What industry is Cooper Pharma in?
Cooper Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors, with a secondary code of HLAIAJAD, Hospital & Health-System Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.